FDA proposal on drug articles under fire

Apr 20, 2008

Claims that the pharmaceutical company Merck hired ghostwriters for Vioxx articles has put heat on a U.S. proposal to loosen drug promotion rules.

The painkiller Vioxx was a top-selling drug before it was taken off the market in 2004 after clinical trials found it increased heart attack risks.

The report on Vioxx, published Wednesday by the Journal of the American Medical Association, brought questions to light regarding the accuracy of peer-reviewed medical research studies, The New York Times reported.

"What does it mean to be peer-reviewed if the company has essentially conceived the article, composed the draft and written the paper?" said Dr. Joseph S. Ross, author of the the JAMA article.

The FDA reportedly has taken a proposal into consideration that would allow drug companies to use peer-reviewed articles for the promotion of off-label drugs the administration has yet to approve.

Public Citizen, New York's state health commissioner and the Blue Cross Blue Shield Association have all said they oppose the FDA plan, the Times reported.

Copyright 2008 by United Press International

Explore further: Allergan to cut 1,500 employees in restructuring (Update)

add to favorites email to friend print save as pdf

Related Stories

FDA panel: Diabetes drug should stay on market

Jul 14, 2010

(AP) -- A majority of federal health experts voted Wednesday to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack.

When is a drug too risky to stay on the market?

Jun 30, 2010

(AP) -- The arthritis pill Vioxx was withdrawn but menopause hormones were not, even though both were tied to heart risks. A multiple sclerosis medicine was pulled and later allowed back on. So, when is a drug too risky to ...

Recommended for you

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

Safety problems at US germ labs acknowledged

Jul 16, 2014

(AP)—The director of the U.S. Centers for Disease Control and Prevention acknowledged Wednesday that systemic safety problems have for years plagued federal public health laboratories that handle dangerous ...

User comments : 0